VERUHealthcare · BiotechnologyThe 2 Wall Street analysts covering Veru, Inc. hold a median 12-month price target of $25 — +794.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 12 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Veru, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (82): Smaller than most of the companies we track.
Value (19): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VERU, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +794.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 June 2026 | Canaccord Genuity | Maintains | Buy | $25 |
| 15 May 2026 | Oppenheimer | Maintains | Outperform | — |
| 18 Dec 2025 | Canaccord Genuity | Initiates | Buy | — |
| 13 Aug 2025 | Raymond James | Maintains | Outperform | — |
| 2 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Nov 2024 | Oppenheimer | Reiterates | Outperform | — |
| 14 May 2024 | B. Riley Securities | Initiates | Buy | — |
| 13 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Apr 2024 | Oppenheimer | Reiterates | Outperform | — |
| 28 Mar 2024 | Raymond James | Initiates | Outperform | — |
| 8 Feb 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 June 2023 | Jefferies | Upgrade | Hold | — |
| 15 May 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Apr 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Mar 2023 | Oppenheimer | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VERU appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 71% of US stocks
Cheaper than 66% of US stocks
Cheaper than 63% of US stocks
Higher than 33% of US stocks
Higher than 30% of US stocks
Higher than 21% of US stocks
Higher than 9% of US stocks
Higher than 91% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Veru, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of Veru, Inc.'s Q3 2026 earnings call. The item relays the company's quarterly earnings discussion.
Why it matters — A Veru watcher would care because the earnings call transcript provides insight into the company's most recent quarterly performance and management commentary.
Veru reported its fiscal 2026 third quarter financial results and provided an update on its Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss, noting the trial is fully enrolled with 239 patients.
Why it matters — Full enrollment of the Phase 2b PLATEAU trial marks a key clinical milestone for Veru's lead investigational weight-loss combination candidate.
Veru announced a notice of allowance for a key U.S. methods-of-use patent covering enobosarm in combination with semaglutide for quality weight loss, providing patent protection until at least October 2044 once issued. This allowed patent adds to already issued enobosarm polymorph composition-of-matter patents and other pending methods-of-use and formulation applications.
Why it matters — A VERU watcher would care because the allowed patent extends intellectual property protection for the enobosarm plus semaglutide combination into 2044, strengthening the company's position around this weight-loss program.
Veru announced it will host a conference call and audio webcast on Monday, August 10, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 third quarter financial results and provide a business update.
Why it matters — The announcement gives Veru watchers the date and venue to hear the company's latest quarterly financial results and business update.
Veru announced that its Chairman, President and CEO, Mitchell Steiner, M.D., will participate in a fireside chat at Canaccord Genuity's 46th Annual Growth Investors Conference in Boston on August 12, 2026.
Why it matters — A VERU watcher would care because the CEO's presentation at an investor conference provides an opportunity for the company to discuss its pipeline and strategy with the investment community.
The 2 Wall Street analysts covering Veru, Inc. have a median 12-month price target of $25, with estimates ranging from $24 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Veru, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Veru, Inc. 39 out of 100 across roughly 4,600 US stocks as at 12 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Aug 2026, Veru, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (82 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +794.2% from the last close, and Ticker Nerd's factor model ranks Veru, Inc. 39 out of 100 as at 12 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Veru, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VERU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $25 over the next 12 months.
Veru, Inc. returned -13.6% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Veru Inc. is a biopharmaceutical company focused on developing and commercializing novel small‑molecule therapies for cardiometabolic and inflammatory diseases.
The most recent item we track (Seeking Alpha, 10 Aug 2026): "Veru Inc. (VERU) Q3 2026 Earnings Call Transcript". Seeking Alpha published the transcript of Veru, Inc.'s Q3 2026 earnings call. The item relays the company's quarterly earnings discussion.
Veru Inc. is a biopharmaceutical company focused on developing and commercializing novel small‑molecule therapies for cardiometabolic and inflammatory diseases. The company’s lead program centers on enobosarm, an oral selective androgen receptor modulator being evaluated to mitigate loss of muscle mass and function in patients undergoing weight loss treatment with GLP‑1–based therapies, aiming to support higher-quality weight reduction by preserving lean tissue. Veru Inc. is also advancing sabizabulin, an oral microtubule disruptor with broad anti-inflammatory properties under development for chronic inflammation associated with atherosclerotic cardiovascular disease and related conditions. In addition, the company maintains programs in oncology and acute respiratory distress syndrome, with late-stage development assets targeting breast and prostate cancer and viral-related ARDS. Veru Inc. currently generates revenue primarily from the United States, South Africa, and other international markets through its commercial sexual health products, including ENTADFI for benign prostatic hyperplasia and the FC2 Female Condom (Internal Condom). Headquartered in Miami, Florida, Veru Inc. operates as a single business segment within the healthcare and biotechnology industry.
CEO Dr. Mitchell S. Steiner F.A.C.S., M.D. · 20 employees · United States · https://verupharma.com